• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 7 shares, decreasing direct ownership by 2% to 342 units (SEC Form 4)

    11/26/24 4:36:18 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XCUR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Miller Josh

    (Last) (First) (Middle)
    C/O EXICURE, INC.
    2430 N. HALSTED ST.

    (Street)
    CHICAGO IL 60614

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    EXICURE, INC. [ XCUR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Accounting Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/16/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/16/2024 F 7(1) D $2.9 342(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares of Common Stock withheld by Exicure, Inc. to cover the reporting person's tax withholding obligation upon the vesting of restricted stock units.
    2. On August 27, 2024, Exicure, Inc. (the "Issuer") effected a one-for-five reverse stock split (the "Reverse Stock Split") as approved at the special meeting of the stockholders of the Issuer on August 15, 2024. As a result, every five shares of Common Stock, par value $0.0001 per share (the "Common Stock"), of the Issuer issued and outstanding were automatically exchanged into one new share of Common Stock, and restricted stock units were adjusted to reflect the Reverse Stock Split. Accordingly, the figures reflect the Reverse Stock Split.
    Remarks:
    /s/ Joshua Miller 11/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $XCUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XCUR

    DatePrice TargetRatingAnalyst
    12/13/2021$2.25 → $0.40Buy → Neutral
    Chardan Capital Markets
    11/23/2021$7.00 → $2.25Buy
    Chardan Capital
    More analyst ratings

    $XCUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

      Exicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2025 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q by May 20, 2025 for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). Under Nasdaq's listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan

      5/28/25 4:58:00 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

      Topline results expected H2 2025 Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukaph

      5/5/25 8:00:00 AM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

      Exicure, Inc. (NASDAQ:XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) (NCT05561751). The study is an open-label, multi-center trial evaluating the safety and efficacy of GPC-100 and propranolol in combination with G-CSF. Data from an interim analysis of 10 patients were previously presented at the 2024 American Society of Hematology (ASH) Annual Meeting. Preliminary results are encouraging, with 100% of patients

      4/14/25 6:11:00 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XCUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      3/26/25 5:41:19 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Dgp Co., Ltd. bought $711,669 worth of shares (237,223 units at $3.00), increasing direct ownership by 39% to 849,223 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      9/16/24 9:41:12 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care